DDW: Probiotic Therapy May Be Effective for Treating Ulcerative Colitis

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

http://www.docguide.com/news/content.nsf/NewsPrint/8525697700573E1885256D2D00744137

To print: Select File and then Print from your browser's menu
 


Title: DDW: Probiotic Therapy May Be Effective for Treating Ulcerative Colitis
 
 
 "DDW: Probiotic Therapy May Be Effective for Treating Ulcerative Colitis"


By Mike Fillon ORLANDO, FL -- May 21, 2003 -- Probiotic therapy might be effective for treating patients with ulcerative colitis, according to research presented here May 19th at Digestive Disease Week 2003. Probiotics -- the use of living organisms, ingested in precise numbers, to improve health -- are generally prepared from a large group of empirically designated lactic acid bacteria (LAB). Lead investigator Richard Fedorak, MD, a professor of medicine and director of the division of gastroenterology at University of Alberta, in Edmonton, Alberta, Canada, said that although the pathogenesis of ulcerative colitis is not clearly understood, evidence suggests that controlling the balance of the intestinal bacterial flora may be very beneficial for these patients. "Many ulcerative colitis patients do not respond to conventional treatments and side effects of these medications can be troublesome," Dr. Fedorak said. "These results are meaningful because they demonstrate that adding a probiotic with multiple strains and a high concentration of bacteria to the treatment regimen may have the potential to stop this disease in its tracks and avoid any treatment-related side effects." In the multicenter, open-label study, 30 patients from Canada, United States, and Italy with a recent flare-up of mild to moderate ulcerative colitis that did not respond to conventional treatment were given four packets daily of the probiotic preparation VSL#3 (equivalent to 3,600 billion good bacteria) for 6 weeks. Eligible patients also remained on steady doses of standard therapies including mesalamine, oral corticosteroids, and azathioprine. The primary end point of remission was determined using the Ulcerative Colitis Clinical Score (UCCS), and was observed in 63% of patients. An additional 23% had an improvement in symptoms, for a combined remission/response rate of 86%. Four patients did not respond to the treatment, with one patient demonstrating worsened disease activity. No adverse biochemical or clinical effects were observed by adding the therapy. Dr. Fedorak said results from the study confirm earlier findings that showed VSL#3 is effective in the management of gastrointestinal disorders such as pouchitis, a major complication following a common surgical procedure in patients with ulcerative colitis. [Study title: VSL3 Probiotic Mixture Induces Remission in Patients with Active Ulcerative Colitis. Abstract 102453]

 
 
Copyright © 2003 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.


Go back

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 2003 P\S\L Consulting Group Inc.
All rights reserved.
 

 

 

 

Return to Vaccination News Home Page

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.